Bio, thanks for the good breakdown of Novocure and here NVCR sits at around 80 bucks a share with all time high of 232 June of last year, just crazy to think about possibilities for NWBO.
UK NICE has a very limited number of oncology treatments they reimburse for. The look at cost-benefit and reject many of the new treatments because they are more costly than generic SoC. It isn't because of trial data as many are superior, it is the incremental cost versus generic chemo.
News 
Market Data 
Discover 
AI
